Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
Objective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-11-01
|
Series: | ACR Open Rheumatology |
Online Access: | https://doi.org/10.1002/acr2.11079 |
id |
doaj-077270b7f0664a2bb3a7d4f9334eb12c |
---|---|
record_format |
Article |
spelling |
doaj-077270b7f0664a2bb3a7d4f9334eb12c2020-11-25T02:03:01ZengWileyACR Open Rheumatology2578-57452019-11-011956057010.1002/acr2.11079Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid ArthritisKaleb Michaud0Bernard Vrijens1Eric Tousset2Sofia Pedro3Rebecca Schumacher4Gorana Dasic5Connie Chen6Ekta Agarwal7Maria E. Suarez‐Almazor8University of Nebraska Medical Center, Omaha, Nebraska and Forward, The National Databank for Rheumatic Diseases Wichita KansasAARDEX Group, Visé, Belgium, and University of Liège Liège BelgiumAARDEX Group Visé BelgiumForward, The National Databank for Rheumatic Diseases Wichita KansasForward, The National Databank for Rheumatic Diseases Wichita KansasPfizer Inc. New York New YorkPfizer Inc. New York New YorkPfizer Inc. New York New YorkUniversity of Texas MD Anderson Cancer Center HoustonObjective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently (12 months or sooner) initiated oral MTX. MEMS was used to compile MTX weekly dosing over 24 weeks. The Beliefs about Medicines Questionnaire (BMQ) was completed, and baseline demographics and disease characteristics obtained. MTX adherence (percentage of weeks dose taken correctly), implementation (percentage of weeks dose taken correctly from initiation until last dose), and persistence (duration from initiation to last dose) were calculated. Analyses measured associations between patient characteristics and adherence, modeled using logistic generalized estimating equations and censored Poisson regression, and persistence modeled using Cox regression. Results Overall, 60 of 119 eligible patients were included in the analysis. MTX adherence, implementation, and persistence were 75%, 80%, and 83%, respectively, at 24 weeks. Demographics and disease characteristics were generally similar between patients with 1 week or less and 2 weeks or more of missed MTX. Unemployment, less disability, higher Patient Global scores, and no prior disease‐modifying antirheumatic drug (DMARD) use were associated with correct dosing. No significant differences in adherence were observed between patients receiving concomitant MTX versus MTX monotherapy, and biologic DMARD‐experienced versus biologic DMARD‐naïve patients. Higher scores in BMQ Specific Necessity (indicating a greater belief in the necessity of the medication) was associated with a decreased likelihood of dosing at an interval shorter than prescribed (odds ratio 0.89). Conclusion Even in a participatory group over a short period, MTX adherence was suboptimal and associated with certain demographics, medication experience, and beliefs about medicines. This suggests a need for screening and alternative treatment opportunities in nonadherent MTX patients with RA.https://doi.org/10.1002/acr2.11079 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kaleb Michaud Bernard Vrijens Eric Tousset Sofia Pedro Rebecca Schumacher Gorana Dasic Connie Chen Ekta Agarwal Maria E. Suarez‐Almazor |
spellingShingle |
Kaleb Michaud Bernard Vrijens Eric Tousset Sofia Pedro Rebecca Schumacher Gorana Dasic Connie Chen Ekta Agarwal Maria E. Suarez‐Almazor Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis ACR Open Rheumatology |
author_facet |
Kaleb Michaud Bernard Vrijens Eric Tousset Sofia Pedro Rebecca Schumacher Gorana Dasic Connie Chen Ekta Agarwal Maria E. Suarez‐Almazor |
author_sort |
Kaleb Michaud |
title |
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis |
title_short |
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis |
title_full |
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis |
title_fullStr |
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis |
title_full_unstemmed |
Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis |
title_sort |
real‐world adherence to oral methotrexate measured electronically in patients with established rheumatoid arthritis |
publisher |
Wiley |
series |
ACR Open Rheumatology |
issn |
2578-5745 |
publishDate |
2019-11-01 |
description |
Objective To assess methotrexate (MTX) adherence using the Medication Event Monitoring System (MEMS) and characterize associations with adherence in patients with rheumatoid arthritis (RA). Methods Eligible patients participated in Forward, the National Databank for Rheumatic Diseases, and recently (12 months or sooner) initiated oral MTX. MEMS was used to compile MTX weekly dosing over 24 weeks. The Beliefs about Medicines Questionnaire (BMQ) was completed, and baseline demographics and disease characteristics obtained. MTX adherence (percentage of weeks dose taken correctly), implementation (percentage of weeks dose taken correctly from initiation until last dose), and persistence (duration from initiation to last dose) were calculated. Analyses measured associations between patient characteristics and adherence, modeled using logistic generalized estimating equations and censored Poisson regression, and persistence modeled using Cox regression. Results Overall, 60 of 119 eligible patients were included in the analysis. MTX adherence, implementation, and persistence were 75%, 80%, and 83%, respectively, at 24 weeks. Demographics and disease characteristics were generally similar between patients with 1 week or less and 2 weeks or more of missed MTX. Unemployment, less disability, higher Patient Global scores, and no prior disease‐modifying antirheumatic drug (DMARD) use were associated with correct dosing. No significant differences in adherence were observed between patients receiving concomitant MTX versus MTX monotherapy, and biologic DMARD‐experienced versus biologic DMARD‐naïve patients. Higher scores in BMQ Specific Necessity (indicating a greater belief in the necessity of the medication) was associated with a decreased likelihood of dosing at an interval shorter than prescribed (odds ratio 0.89). Conclusion Even in a participatory group over a short period, MTX adherence was suboptimal and associated with certain demographics, medication experience, and beliefs about medicines. This suggests a need for screening and alternative treatment opportunities in nonadherent MTX patients with RA. |
url |
https://doi.org/10.1002/acr2.11079 |
work_keys_str_mv |
AT kalebmichaud realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT bernardvrijens realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT erictousset realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT sofiapedro realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT rebeccaschumacher realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT goranadasic realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT conniechen realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT ektaagarwal realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis AT mariaesuarezalmazor realworldadherencetooralmethotrexatemeasuredelectronicallyinpatientswithestablishedrheumatoidarthritis |
_version_ |
1724949920133152768 |